Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide

被引：4

作者：

Lu, Shan ^{[1
]}

Tan, Zongqin ^{[1
]}

Wortman, Matthew

Lu, Shan ^{[1
]}

Dong, Zhongyun ^{[1
]}

机构：

[1] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH 45267 USA

来源：

CANCER LETTERS | 2010年 / 298卷 / 02期

关键词：

Androgen receptor; Antagonist; Prostate cancer; Cell cycle; DOWN-REGULATION; IN-VITRO; LNCAP; INHIBITION; EXPRESSION; PROLIFERATION; QUERCETIN; APOPTOSIS; GROWTH; MECHANISMS;

D O I：

10.1016/j.canlet.2010.07.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The purpose of this study was to further characterize cell growth-inhibitory effects of a recently identified androgen receptor (AR) signaling inhibitor 6-amino-2-[2-(4-tertbutyl-pnenoxy)-ethylsulfanyl]-1H-pyrimidin-4-one (DL3)(5) and antiandrogen bicalutamide (Bic) DO was more potent than Bic in induction of G1 arrest and reduction of G1-related cell cycle protein expression in AR-positive LNCaP cells DL3 but not Bic moderately inhibited growth of AR-negative PC-3 cells independent of Cl arrest The data indicated that DL3 inhibit cell growth in both AR-dependent and -independent manners and is potentially a potent therapeutic agent for the management of advanced human prostate cancer Published by Elsevier Ireland Ltd

引用

页码：250 / 257

页数：8

共 36 条

[1] Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins [J].

Aziz, Moammir H. ;

Nihal, Minakshi ;

Fu, Vivian X. ;

Jarrard, David F. ;

Ahmad, Nihal .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) :1335-1341

[2]

Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001

[3] RETRACTED: Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells (Retracted article. See vol. 78, pg. 5473, 2018) [J].

Bhuiyan, Mohammad M. R. ;

Li, Yiwei ;

Banerjee, Sanjeev ;

Ahmed, Fakhara ;

Wang, Zhiwei ;

Ali, Shadan ;

Sarkar, Fazlul H. .

CANCER RESEARCH, 2006, 66 (20) :10064-10072

[4] Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth [J].

Cha, TL ;

Qiu, L ;

Chen, CT ;

Wen, Y ;

Hung, MC .

CANCER RESEARCH, 2005, 65 (06) :2287-2295

[5]

Chinni SR, 2002, CLIN CANCER RES, V8, P1228

[6] Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer [J].

Chun, JY ;

Nadiminty, N ;

Lee, SO ;

Onate, SA ;

Lou, W ;

Gao, AC .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :913-918

[7] Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications [J].

Ciocca, DR ;

Calderwood, SK .

CELL STRESS & CHAPERONES, 2005, 10 (02) :86-103

[8] The complex role of AR signaling after cytotoxic insult - Implications for cell cycle based chemotherapeutics [J].

Comstock, Clay E. S. ;

Knudsen, Karen E. .

CELL CYCLE, 2007, 6 (11) :1307-1313

[9] CHALLENGES IN THE MANAGEMENT OF PROSTATE-CANCER [J].

CRAWFORD, ED .

BRITISH JOURNAL OF UROLOGY, 1992, 70 :33-38

[10] Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer [J].

Dong, Zhongyun ;

Liu, Yin ;

Lu, Shan ;

Wang, Amy ;

Lee, Kiwon ;

Wang, Lu-Hai ;

Revelo, Monica ;

Lu, Shan .

MOLECULAR ENDOCRINOLOGY, 2006, 20 (10) :2315-2325

← 1 2 3 4 →